ScholarIQanswers from OpenAlex
People’s University
InstitutionResearch output, impact & collaborations
People’s University is a institution indexed in ScholarIQ from OpenAlex.
What is known about People’s University?
ScholarIQrecord summary
People’s University is a research organisation in Bhopal, IN. OpenAlex records 3,625 works and 56,175 citations for it. 1,369 researchers list it as their most recent affiliation.
How many works does People’s University have?
ScholarIQindexed works
People’s University has 3,625 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does People’s University have?
ScholarIQcitation count
People’s University has 56,175 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at People’s University?
ScholarIQresearcher count
People’s University has 1,369 researchers in the ScholarIQ index.
What is the average h-index at People’s University?
ScholarIQavg h-index
People’s University has an average h-index of 55 in OpenAlex.
What is the ROR of People’s University?
ScholarIQror
The ROR for People’s University is on the source record.
What is the OpenAlex record for People’s University?
ScholarIQopenalex
The OpenAlex for People’s University is on the source record.
Who are the most-cited researchers behind People’s University?
ScholarIQtop researchers by citations
What are the most-cited papers on People’s University?
ScholarIQmost cited works
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, Janice Dutcher, Robert A. Figlin, Anil Kapoor, Elżbieta Starosławska, Jeffrey A. Sosman, David McDermott, I. Bodrogi, Zoran Kovačević, Vladimir Lesovoy, Ingo G.H. Schmidt‐Wolf, О. Л. Барбараш, Erhan Gökmen, Timothy E. O’Toole, Stephanie Lustgarten, Laurence Moore, Robert J. Motzer
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, Ugo De Giorgi, Tomáš Büchler, Naveen S. Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas E. Hutson, C. Alemany, Bradley A. McGregor, Thomas Powles, Viktor Grünwald, B. Yа. Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Michael Staehler, Jaime R. Merchan, Ran Xie, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Camillo Porta
How much of the research on People’s University is open access?
ScholarIQopen access share
67%OPEN ACCESS